Perrigo (NYSE:PRGO) Trading 5.7% Higher – Time to Buy?

Perrigo Company plc (NYSE:PRGO) rose 5.7% on Thursday . The company traded as high as $10.71 and last traded at $10.73. 164,647 shares were traded during mid-day trading, a decline of 95% from the average session volume of 3,196,631 shares. The stock had previously closed at $10.15.

Analysts Set New Price Targets

PRGO has been the topic of several recent analyst reports. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Perrigo has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Trading Down 3.9%

The company has a 50-day moving average of $10.66 and a 200 day moving average of $11.92. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The company has a market cap of $1.48 billion, a PE ratio of -0.82, a price-to-earnings-growth ratio of 1.33 and a beta of 0.51.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $841.80 million for the quarter, compared to the consensus estimate of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The company’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Investors of record on Friday, May 29th were given a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a yield of 10.8%. Perrigo’s dividend payout ratio (DPR) is currently -8.85%.

Institutional Investors Weigh In On Perrigo

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB lifted its holdings in shares of Perrigo by 20.7% in the 2nd quarter. Handelsbanken Fonder AB now owns 50,200 shares of the company’s stock worth $522,000 after acquiring an additional 8,600 shares during the last quarter. GAMMA Investing LLC grew its holdings in Perrigo by 58.3% during the 2nd quarter. GAMMA Investing LLC now owns 14,733 shares of the company’s stock valued at $153,000 after purchasing an additional 5,427 shares during the last quarter. Bank of America Corp DE raised its position in Perrigo by 25.5% in the 1st quarter. Bank of America Corp DE now owns 1,568,598 shares of the company’s stock worth $16,847,000 after purchasing an additional 318,248 shares during the period. RBF Capital LLC bought a new stake in Perrigo in the first quarter worth about $1,933,000. Finally, Parvin Asset Management LLC boosted its position in shares of Perrigo by 51.4% during the first quarter. Parvin Asset Management LLC now owns 19,875 shares of the company’s stock valued at $213,000 after buying an additional 6,750 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.